“In situ” vaccination for systemic effects in follicular lymphoma

Abstract

Therapeutic vaccines for follicular lymphoma have had limited success. A novel in situ immunotherapeutic strategy combining 3 different treatment modalities induced regression of disseminated follicular lymphoma, which correlated with systemic antitumor T-cell immunity. These results should renew interest in the development of local combined radio- and immunotherapies to achieve abscopal effects.